TO THE EDITOR Bowenoid papulosis (BP) is a disease characterized by multiple brown-toblack papules on the genitalia and histological changes similar to Bowen's disease, ranging from low to severe dysplasia. The high-risk, oncogenic human papillomavirus (HPV) type 16 has been found in most cases of BP (Porter et al., 2002; Gross and Pfister, 2004) . Several studies have shown that the transition of intraepithelial precursor lesions to carcinoma (in situ) is associated with integration of the virus into the cellular genome (Zur Hausen, 2002; Hopman et al., 2004) . In situ hybridization can efficiently identify the physical status of HPV in tissue cells, as punctate and diffuse nuclear signals correlate with restriction digestion and Southern blot hybridization results to detect integrated or replicative (episomal) HPV, respectively (Cooper et al., 1991) . So far, data linking viral integration to recurrence and progression of BP lesions are scarce.
Common treatment modalities of penile lesions such as BP include excision, circumcision, electrodessication, laser ablation, cryotherapy, photodynamic therapy, and local administration of 5-fluorouracil-containing cream (Porter et al., 2002; Endo et al., 2003) . Recurrence rates, however, are high and persistent lesions are regarded as a precursor to malignancy (Gross and Pfister, 2004) . Therefore improvement of therapeutic strategies is needed. Imiquimod is a topical immune response modifier inducing the production of cytokines from monocytes and macrophages, thus stimulating the T-helper 1 response and most probably also cytotoxic T-cell activation and a B-cell response (Slade et al., 1998; Suzuki et al., 2000) . In addition, imiquimod is believed to have antiangiogenic activity (Li et al., 2005) . Because imiquimod treatment has proven effective in combating viral infections as well as reducing (pre)malignant epithelial lesions (Hannuksela-Svahn et al. 2000; Mackenzie-Wood et al., 2001; Petrow et al., 2001) , we applied this treatment to two patients presenting with obstinate BP lesions of which the presence and physical status of HPV was determined before and after treatment.
A 40-year-old male patient was referred to our clinic with a 6-month history of slightly pruritic penile papules. On clinical examination multiple erythematous papules were seen on the penile shaft, glans, and foreskin ( Figure  1a ). Histological examination revealed full-thickness epithelial dysplasia, supporting the clinical diagnosis of BP ( Figure 1b ). PCR amplification on extracted DNA from this lesion demonstrated infection with oncogenic HPV (Figure 1c , lane 4), which turned out to be type 16 after enzyme immunoassay typing (Van den Brule et al., 2002) . Fluorescent in situ hybridization (FISH) analysis using a HPV-16-specific probe showed diffuse staining of cell nuclei indicating the presence of episomal HPV in the lesion (Figure 1d ) (Hafkamp et al., 2003) . Treatment with imiquimod 5% cream for 16 weeks was started. The cream was applied once daily, three times a week. After 1 month a substantial improvement was observed and after 16 weeks all skin lesions had completely disappeared ( Figure 1f ). Histological examination of a skin biopsy tissue section 1 month after imiquimod treatment showed inflammation and complete absence of epithelial dysplasia (Figure 1g ). This finding coincided with disappearance of the virus from the lesion, as revealed by PCR ( Figure 1c , lane 5) and FISH analysis (Figure 1e ). Nine months after discontinuation of treatment no relapse was observed. The authors declare that the study received institutional approval, patients gave their informed consent, and experiments were conducted according to the principles for Medical Research Involving Human Subjects defined by the World Medical Association the Declaration of Helsinki Principles.
A 76-year-old male patient visited our clinic because of itching erythematous papules and plaques on the penile glans and shaft. Histological examination of a biopsy revealed hyperkeratosis, hyperplasia with cytonuclear atypia, and mitoses (Figure 1h ). Both clinical presentation and histopathology supported the diagnosis of BP. PCR amplification on genomic DNA extracted from this biopsy showed also infection with HPV type 16 (Figure 1c, lane 7) . Interestingly, FISH analysis revealed predominantly two punctate signals per nucleus, indicating a pair of chromosomes with a single HPV16 integration site (data not shown). First, treatment with ablative CO 2 /Erbium laser was performed to eliminate the lesions on the glans and penile shaft. Six weeks after this laser treatment the skin eruption relapsed. We then started treatment with imiquimod 5% cream. The lesions reduced in size but there were still little small plaques on the glans penis visible after 16 weeks. One month after treatment a new biopsy of a lesion was taken and showed no dysplasia of the epithelium (Figure 1i ). However, molecular analysis showed persistence of the viral infection by PCR (Figure 1c, lane 8) and FISH analysis (Figure 1j ).
Our molecular examination of the BP lesions before treatment revealed the presence of HPV-16 in the episomal form in the complete responder, whereas viral integration was observed in the partial responder. These results indicate that triggering of the host immune response by imiquimod is especially efficient if oncogenic HPV is replicating in the BP lesion and integration in the cellular DNA has not taken place. The various HPVexpressed early and late proteins may all contribute to effective T-and B-cell responses (Jenson et al., 1991; Hö pfl et al., 2000; Tindle, 2002; Van Poelgeest et al., 2005) . In case of viral integration, however, which is associated with a higher risk for malignancy, the HPV genome is usually disrupted within the E2 gene and also E4, E5, and part of L2 are regularly deleted (Zur Hausen, 2002) . As a consequence potential targets for T-cell responses are eliminated. Moreover, viral integration leads to high levels of viral oncoproteins E6 and E7, which have been shown to downregulate the cell cycle regulatory proteins P53 and phosphorylated Rb to maintain keratinocytes in the cell cycle as well as to effectively suppress cellular and interferon-mediated immune responses in addition (Tindle, 2002) . In such cases, vaccination of patients with a therapeutic vaccine based on the HPV-encoded oncoproteins E6 and E7 may be indicated in the near future, because they have shown encouraging results in (pre)clinical settings (Albers et al., 2005; Govan, 2005) .
In conclusion, imiquimod treatment provides a promising alternative therapy for BP, particularly in cases in which treatment is started whereas HPV is replicating and present in the episomal form. Our results suggest that BP lesions showing viral integration into the cellular genome may persist after imiquimod treatment. After treatment discontinuation a control biopsy for HPV staining is recommended to determine the efficacy of imiquimod in the individual patient. A higher proportion of cases will be necessary to further substantiate our findings.
